二氟乙酸乙酯 、 4'-三氟甲基苯乙酮 以to give 4,4-difluoro-1-(4-trifluoromethyl-phenyl)-butane-1,3-dione (21.60 g, 101%) as a light brown oil的产率得到4,4-difluoro-1-(4-trifluoromethyl-phenyl)-butane-1,3-dione
Substituted pyrazolyl benzenesulfonamide for the treatment of
申请人:G.D. Searle & Co.
公开号:US05521207A1
公开(公告)日:1996-05-28
A class of pyrazolyl benzenesulfonamide compounds is described for use in treating inflammation and inflammation-related disorders. Compounds of particular interest are defined by Formula I: ##STR1##
A class of pyrazolyl benzenesulfonamide compounds is described for use in treating inflammation and inflammation-related disorders. Compounds of particular interest are defined by Formula I: ##STR1## or a pharmaceutically-acceptable salt thereof.
[EN] PYRAZOLO AND IMIDAZO-PYRIMIDINE DERIVATIVES<br/>[FR] DERIVES DE PYRAZOLO-PYRIMIDINE ET D'IMIDAZO-PYRIMIDINE
申请人:HOFFMANN LA ROCHE
公开号:WO2005040171A1
公开(公告)日:2005-05-06
The present invention relates to novel pyrazolo- and imidazo-pyrimidine derivatives of formula (I) wherein A, D, E, L, M, Q, R1, R2 and R3 are as defined in the description and claims and to processes for their preparation, pharmaceutical compositions containing said derivatives and their use in the prevention and treatment of diseases.
[EN] PYRRAZOLO-PYRIMIDINE DERIVATIVES<br/>[FR] DERIVES DE PYRRAZOLO-PYRIMIDINE
申请人:HOFFMANN LA ROCHE
公开号:WO2005123738A1
公开(公告)日:2005-12-29
The invention relates to compounds of formula (I) wherein R1, R2, R3, R4, R5 and p are as defined in the description and claims as well as to pharmaceutically acceptable salts thereof per se and as pharmaceutically active substances, their manufacture, medicaments based on a compound in accordance with the invention and their production, as well as the use of the compounds in accordance with the invention in the control or prevention of illnesses of the aforementioned kind, and, respectively, for the production of corresponding medicaments.
The present invention relates to pyrrazolo-pyrimidine derivatives of formula (I):
wherein R
1
to R
4
and A are as defined in the specification, a process for the manufacture thereof, their use for treating or preventing metabotropic glutamate receptors mediated disorders, their use for the preparation of medicaments for treating such disorders and pharmaceutical compositions containing said derivatives.